Dose: 5 to 10 mg/kg/day
Single Dose: 7.5 (7.5)
Frequency: 24 hourly
Route: PO
Instructions: For paget disease: Dose should not to exceed 6 mo.For retreatment, initiate only after etidronate-free period of at least 90 days and if there is evidence of active disease.

belongs to Bisphosphonate. . The Molecular Weight of Disodium Etidronate is 250.00.

Disodium Etidronate is contraindicated in conditions like Pregnancy,Breast feeding,Pain and inflammation (rheumatic disease),Vasomotor symptoms in estrogen deficiency, see instruction.

The symptomatic adverse reactions produced by Disodium Etidronate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Skin reactions, Constipation, Abdominal pain, Urticaria, Pruritus, Increased bone pain in paget`s disease.

'Disodium Etidronate is primarily indicated in conditions like Osteoporosis, Paget''s disease of bone, Sedation with amnesia, Severe hypercalcaemia.'

No data regarding the interactions of Disodium Etidronate was found.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Disodium Etidronate should be used with caution in renal impairment (reduce dose in mild, avoid if moderate to severe). MONITORING: Serum phosphate, serum alkaline phosphatase and (if possible) urinary hydroxyproline should be measured before starting and at intervals of 3 months---consult product literature for further information. COUNSELLING: Avoid food for atleast 2 hours before and after oral treatment perticularly calcium-containing products e.g milk; also avoid iron and mineral supplements and antacids.